About
Breath of Life (BOL) Pharma is developing cannabinoid-based drugs to improve patients' health and quality of life with high-quality botanical-derived products. BOL Pharma cultivates and farms its own proprietary cannabis strains, has state-of-the-art certified labs, and owns a plant and a distribution center.
BOL Pharma addresses the medical cannabis, wellness, and pharmaceutical markets. The pharmaceutical division has launched a spinoff company, with an inhaler based on a Kindeva drug delivery platform (formerly 3M DDS) for selected pain indications as its core product.
This pressurized metered dose inhaler (pMDI) contains cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) for multiple sclerosis-related neuropathic pain (lead indication). Additional follow-on planned indications include chemotherapy-induced and HIV-induced neuropathic pain.
The cannabinoid-based pMDI is a combination product of drug/drug/device and offers an efficient administration route of delivery compared to oral delivery. Inhalation of THC/CBD avoids irregular gastrointestinal absorption and first-pass hepatic metabolism. This leads to increased bioavailability and improved pharmacokinetics of THC/CBD (reduction in inactive circulating metabolites, larger fraction of active parent THC/CBD). It also delivers a rapid, consistent, reproducible dose, and is safe (inhalation may reduce hepatoxicity concerns, as lung absorption bypasses first-pass hepatic metabolism) and easy to use (breath actuated, no special preparation required). The technology is based on a pharmaceutically well-known inhaler device and is environmentally friendly, using low global-warming-potential propellants. The IP-protected device (with additional IP generated during clinical development) addresses the need for non-opioid analgesics, with a quick onset of action.
Funding history · 2 rounds · $35.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the current operational status of Breath of Life Pharma?
- Breath of Life Pharma is currently inactive, having ceased operations in April 2025.
- What is Breath of Life Pharma's primary focus in product development?
- Breath of Life Pharma is developing cannabinoid-based drugs, including a pressurized metered dose inhaler (pMDI) containing CBD and THC for multiple sclerosis-related neuropathic pain, with additional indications planned for chemotherapy-induced and HIV-induced neuropathic pain.
- What was the total amount of funding raised by Breath of Life Pharma?
- Breath of Life Pharma raised a total of $35 million in funding. For a full financing history, please refer to startupim.
- Which companies invested in Breath of Life Pharma's Convertible Debt round in October 2018?
- In October 2018, Gandyr Investments and OurCrowd were among the investors in Breath of Life Pharma's $30 million Convertible Debt round.
- What was a significant partnership announced by Breath of Life Pharma in December 2020?
- In December 2020, Breath of Life Pharma signed an agreement with Kindeva for the development of inhaled cannabinoid products.
- What was a notable event regarding Israel's cannabis exports involving Breath of Life Pharma in January 2020?
- In January 2020, Israel's first-ever cannabis export was completed as LYPHE Group imported products into the UK, involving Breath of Life Pharma.
- What was the outcome of Breath of Life Pharma's planned IPO in Toronto in June 2019?
- In June 2019, Breath of Life Pharma delayed its Toronto IPO and slashed 17% off its pre-IPO valuation.
- What was the employee count of Breath of Life Pharma?
- Breath of Life Pharma had between 11 and 50 employees, with an exact count of 37.